The BRD4 and HIF-1α induced binding to the histone 3/4 acetylation-modified AR promoter, while the BRD4-selective inhibitor JQ1 decreased this binding, ameliorating adverse expressions in PCOS ovarian and DHEA-treated granulosa cells [12]. This evidence concerns the gene BRD4 and polycystic ovary syndrome.